{"schema_version":"secwatch.filing_event.v1","accession":"0000200406-25-000003","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2025-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.778932+00:00","generated_at":"2026-05-27T21:18:06.154221+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"JNJ Q4 net earnings down 17%, revenue up 5.3% to $22.52B; adjusted EPS $2.04","bullets":["Q4 sales $22.52B, +5.3% YoY; net earnings $3.43B, -17% from $4.13B; diluted EPS $1.41.","Adjusted net earnings $4.95B, adjusted EPS $2.04, down 10.9% from $2.29.","Innovative Medicine (ex-COVID) sales $14.33B (+4.8%); MedTech sales $8.19B (+6.7%).","R&D expense rose 18.3% to $5.30B; operating margin contracted to 17.3% from 22.6%.","Full-year sales $88.82B, +4.3% vs $85.16B; ex-COVID sales +5.5%."],"urls":{"canonical":"https://secwatch.observer/filing/0000200406-25-000003","json":"https://secwatch.observer/filing/0000200406-25-000003.json","markdown":"https://secwatch.observer/filing/0000200406-25-000003.md","text":"https://secwatch.observer/filing/0000200406-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000020040625000003/0000200406-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000020040625000003/jnj-20250122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T21:18:06.154221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}